Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Amicus Therapeutics announce revised Fabry agreement
GSK & Amicus announced that Amicus has obtained global rights to develop chaperone migalastat HCl as monotherapy for Fabry disease.
-
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD
GSK & THRX announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®.
-
Five inspirational organisations from Malawi, Bangladesh, Mali, Kenya, and Colombia recognised by GSK and Save the Children
A simple low-cost device that helps newborn babies to breathe has been awarded $1million in the first GSK and Save the Children Award
-
GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease
Study did not meet the primary endpoint measure.
-
GSK names inaugural winners in unique competition for academic drug hunters
GSK announced selection of eight winners in its first Discovery Fast Track competition.
-
GSK announces new apprentice and graduate engineering opportunities in the UK during Tomorrow’s Engineers Week
GSK today announced the recruitment of 140 new apprentices over the next two years in the UK - of which a third will be in engineering.
-
GSK announces data to support Cervarix® two-dose schedule for the prevention of cervical cancer in 9-14 year old girls
GSK today announced the results of a Phase III study of its HPV vaccine, Cervarix.
-
New partnership between GSK and the Bill & Melinda Gates Foundation to accelerate research into vaccines for global health needs
GSK & BMGF announced the launch of initiative that will endeavour to make vaccines more resistant to heat, reducing need for refrigeration.
-
GSK to create a new Centre of Excellence for Sustainable Chemistry in Brazil
GSK announced it's formed new collaboration with FAPESP to create a new Centre of Excellence for Sustainable Chemistry in Brazil.
-
ViiV Healthcare announces European regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV announced submission in EU for STR combining dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) for treatment of people with HIV.
-
Synflorix™ receives positive opinion from the CHMP in Europe for additional pneumonia indication
GSK announced that CHMP has issued a positive opinion for Synflorix™, a paediatric pneumococcal conjugate vaccine.
-
GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma
GSK announced the submission of a New Drug Application in the US for ICS treatment, FF administered using the ELLIPTA™ dry powder inhaler.
-
Results announcement for the third quarter 2013
GSK announces Q3 core EPS growth of 16% and dividend of 19p
-
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV announced submission application in the US for STR combining dolutegravir, abacavir and lamivudine for treatment of people with HIV-1.
-
Regulatory update – GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab A/S announced today the submission of a supplemental Biologics License Application to the US Food and Drug Administration
-
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate.
-
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK & Genmab A/S announced submission of Marketing Authorisation for Arzerra in combination with alkylator-based therapy, for CLL patients
-
GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion
Divestment supports strategic focus and delivery of pipeline.
-
GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia
GSK & Barclays have formed partnership which aims to increase affordable healthcare for people in Zambia, improving economic conditions
-
GSK receives marketing authorisation from the European Commission for additional Revolade™
GSK announced that the EC has granted Revolade™ as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection.